FILTER
FILTERED INTERVIEW RESULTS
Martin Sack
REGIONAL HEAD – AMERICAS, LESCHACO
Leschaco sees a buoyant market for the Latin American chemical trade, but major transport disruptions are a major issue.
Francisco Errazuriz & Jorge Rios
CEO & COMMERCIAL MANAGER, SKC MAQUINARIAS CHILE
SKC Maquinarias Chile believes that adaptability and technology will be fundamental in servicing its mining clients.
Simao Antunes
GENERAL MANAGER SOUTH AMERICA, HOFMANN ENGINEERING
Hofmann Engineering explains how it is expanding into South America.
Francisco Casas
GENERAL MANAGER, NEXXO
Nexxo explains how its experience in mechanical maintenance for the petroleum industry is being put to use by Chile’s miners.
Fernando Porcile & Eduardo Covarrubias
EXECUTIVE CHAIRMAN & DIRECTOR, LOS ANDES COPPER
Los Andes Copper updates GBR on progress at its Vizcachitas project in Chile.
Marcelo Schumacker
COUNTRY DIVISION MANAGER, ABB CHILE
ABB explains why Chile provides an excellent market for its mining technologies.
Sandro Tavonatti
CEO, SIGDO KOPPERS INGENIERÍA Y CONSTRUCCIÓN (SKIC)
Sigdo Koppers Ingeniería y Construcción (SKIC) explains how it operates with Chile’s largest mines.
Hugo Salamanca
PRESIDENT, HIGHSERVICE CORP
HighService Corp in Chile explains its’ vision is to become a leading robotics company worldwide in the mining and heavy industry sectors.
Fernando de la Lastra & Joerg von Loebenstein
GENERAL MANAGER AND CO-FOUNDER & ENGINEERING MANAGER AND CO-FOUNDER, TECNIPAK
Technopak in Chile explains how its specialisation in mineral conveyer systems offers global potential.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
